Lexicon Pharmaceuticals is a biopharmaceutical company that discovers and develops treatments for various diseases. The company markets INPEFA (sotagliflozin), a once-daily oral medication for heart failure and related cardiovascular conditions in adults with type 2 diabetes or chronic kidney disease, and ZYNQUISTA (sotagliflozin) for type 1 diabetes management. Its pipeline includes LX9851, a candidate for obesity and cardiometabolic disorders, and pilavapadin, a candidate for neuropathic pain treatment, supported by partnerships with Viatris and Bristol-Myers Squibb.

entry readiness 32 · NOT READY · exit proximity 15

Value area 1.92–2.52 · 80% of 120d volume overhead · heavy supply